Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?

Executive Summary

Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?

Advertisement

Related Content

Avinger Invests In Trials Of Lumivascular Peripheral Atherectomy Device As Company Restructures
Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
After Atherectomy: Shockwave Medical Preps For Success
Amir Belson: Stealth Medtech Entrepreneur
Total Occlusions: Device Obstacle or Opportunity?
John Simpson: Reluctant Entrepreneur
LuMend's Breakthrough Break Out

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel